Keveyis Approved for Periodic Paralysis
August 10, 2015 – The U.S Food and Drug Administration (FDA) granted approval for Taro Pharmaceutical Industries’ Keveyis (dichlorphen-amide). Keveyis is an oral carbonic anhydrase inhibitor, indicated for the treatment of primary hyperkalemic and hypokalemic periodic paralysis.
Keveyis is the first medication approved by the FDA to treat primary periodic paralysis, an inherited disorder that causes episodes of muscle weakness of paralysis. Approximately 5,000 patients in the U.S. have primary periodic paralysis.
The recommend starting dose for Keveyis is 50mg twice daily, titrated up to a maximum dose of 200mg per day. Taro Pharmaceutical plans to launch Keveyis in the 3rd quarter of 2015, and will be made available through limited distribution.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.